Research programme: ocular therapeutics - Genisphere

Drug Profile

Research programme: ocular therapeutics - Genisphere

Alternative Names: G8-3DNA-Dox; GL-249

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Genisphere
  • Class DNA; Immunoconjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Postoperative inflammation

Most Recent Events

  • 09 Jun 2016 GL 249 is available for licensing as of 09 Jun 2016.
  • 01 May 2016 Preclinical trials in Postoperative Inflammation in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top